Why the study?
Does the choice of beta-blocker affect the risk of hemorrhagic events in chronic heart failure patients on warfarin?
Does the choice of beta-blocker affect the risk of hemorrhagic events in chronic heart failure patients on warfarin?
In chronic heart failure patients on warfarin, the risk of hemorrhagic events varies depending on the specific beta-blocker prescribed, with carvedilol associated with a lower risk compared to metoprolol or atenolol.
Answers are grounded in this paper and cite their sources.
May support preferring carvedilol to limit bleeding risk in HF patients on warfarin; hypothesis-generating and requires randomized confirmation.
PURPOSE: Beta-blockers have many different physiologic effects that could potentially influence the risk of hemorrhagic events in chronic heart failure patients (CHF) on warfarin. We examined how different beta-blockers vary in their associated risk of a hemorrhagic event. METHODS: We used databases from the Department of Veterans Affairs (VA) that contain information on medications prescribed, diagnoses, and hospitalizations. We identified patients with CHF on warfarin and either metoprolol, carvedilol, atenolol, or no beta-blocker during 1999-2001. We modeled time to first hemorrhagic event using a Cox proportional hazards model, adjusting for age, ethnicity, comorbidities, and other factors. INR levels were examined in a subsample of 3546 patients. RESULTS: We identified 66,988 CHF patients on warfarin. Hemorrhagic events occurred in 15.3% of the sample and, in 3.8% of the sample, the hemorrhage was considered severe. Compared to patients on carvedilol, the hazards ratio for a new hemorrhagic event was 1.25 (1.17, 1.34) for no beta-blocker, 1.27 (1.18, 1.38) for atenolol, and 1.38 (1.28, 1.48) for metoprolol. No differences in INR levels were evident among the four groups. CONCLUSIONS: The risk for a hemorrhagic event among CHF patients on warfarin may be affected by beta-blocker use and varies depending on which beta-blocker is prescribed.
No takes yet. Share an insight, caveat, or question.
Berlowitz et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: